Portage Biotech Inc (PRTG) - Net Assets
Based on the latest financial reports, Portage Biotech Inc (PRTG) has net assets worth $695.00K USD as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.71 Million) and total liabilities ($2.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Portage Biotech Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $695.00K |
| % of Total Assets | 25.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -100.56% |
| 10-Year Change | -106.71% |
| Growth Volatility | 1477.74 |
Portage Biotech Inc - Net Assets Trend (1998–2025)
This chart illustrates how Portage Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Portage Biotech Inc for the complete picture of this company's asset base.
Annual Net Assets for Portage Biotech Inc (1998–2025)
The table below shows the annual net assets of Portage Biotech Inc from 1998 to 2025. For live valuation and market cap data, see Portage Biotech Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $-827.00K | -124.84% |
| 2024-03-31 | $3.33 Million | -95.58% |
| 2023-03-31 | $75.39 Million | -54.43% |
| 2022-03-31 | $165.43 Million | +12.08% |
| 2021-03-31 | $147.60 Million | +1.35% |
| 2020-03-31 | $145.64 Million | -1.96% |
| 2019-03-31 | $148.56 Million | +1444.41% |
| 2018-03-31 | $9.62 Million | -83.86% |
| 2017-03-31 | $59.59 Million | +383.36% |
| 2016-03-31 | $12.33 Million | +199.59% |
| 2015-03-31 | $4.12 Million | -18.85% |
| 2014-03-31 | $5.07 Million | +69.95% |
| 2013-03-31 | $2.98 Million | -38.50% |
| 2012-03-31 | $4.85 Million | -45.72% |
| 2011-03-31 | $8.94 Million | +32.06% |
| 2010-03-31 | $6.77 Million | +493.17% |
| 2009-03-31 | $1.14 Million | -77.33% |
| 2008-03-31 | $5.03 Million | -12.36% |
| 2007-03-31 | $5.74 Million | +26.65% |
| 2006-03-31 | $4.53 Million | +10.79% |
| 2005-03-31 | $4.09 Million | +141.80% |
| 2004-03-31 | $1.69 Million | +889.95% |
| 2003-03-31 | $-214.26K | -7111.26% |
| 2002-03-31 | $3.06K | -99.37% |
| 2001-03-31 | $481.93K | -69.86% |
| 2000-03-31 | $1.60 Million | +1394.82% |
| 1999-03-31 | $106.97K | +123.60% |
| 1998-03-31 | $-453.32K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Portage Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23455476100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $245.33 Million | % |
| Total Equity | $-123.00K | 100.00% |
Portage Biotech Inc Competitors by Market Cap
The table below lists competitors of Portage Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wave Entertainment Public Company Limited
BK:WAVE
|
$10.71 Million |
|
Adavale Resources Ltd
AU:ADD
|
$10.71 Million |
|
Metal Bank Ltd
AU:MBK
|
$10.71 Million |
|
QT Imaging Holdings Inc. Common Stock
NASDAQ:QTI
|
$10.72 Million |
|
Kmi Wire And Cable Tbk
JK:KBLI
|
$10.70 Million |
|
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
|
$10.67 Million |
|
Artemis Resources Ltd
AU:ARV
|
$10.67 Million |
|
Finsbury Growth & Income Trust
LSE:FGT
|
$10.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Portage Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,022,000 to -123,000, a change of -4,145,000 (-103.1%).
- Net loss of 6,767,000 reduced equity.
- New share issuances of 2,150,000 increased equity.
- Other comprehensive income decreased equity by 23,841,000.
- Other factors increased equity by 24,313,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.77 Million | -5501.63% |
| Share Issuances | $2.15 Million | +1747.97% |
| Other Comprehensive Income | $-23.84 Million | -19382.93% |
| Other Changes | $24.31 Million | +19766.67% |
| Total Change | $- | -103.06% |
Book Value vs Market Value Analysis
This analysis compares Portage Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-03-31 | $-287.27 | $4.70 | x |
| 1999-03-31 | $35.11 | $4.70 | x |
| 2000-03-31 | $5532.89 | $4.70 | x |
| 2001-03-31 | $74.68 | $4.70 | x |
| 2002-03-31 | $0.43 | $4.70 | x |
| 2003-03-31 | $-20.76 | $4.70 | x |
| 2004-03-31 | $46.17 | $4.70 | x |
| 2005-03-31 | $34.80 | $4.70 | x |
| 2006-03-31 | $28.73 | $4.70 | x |
| 2007-03-31 | $21.05 | $4.70 | x |
| 2008-03-31 | $17.45 | $4.70 | x |
| 2009-03-31 | $3.78 | $4.70 | x |
| 2010-03-31 | $16.57 | $4.70 | x |
| 2011-03-31 | $11.39 | $4.70 | x |
| 2012-03-31 | $6.16 | $4.70 | x |
| 2013-03-31 | $3.65 | $4.70 | x |
| 2014-03-31 | $1.34 | $4.70 | x |
| 2015-03-31 | $1.38 | $4.70 | x |
| 2016-03-31 | $4.28 | $4.70 | x |
| 2017-03-31 | $21.89 | $4.70 | x |
| 2018-03-31 | $3.57 | $4.70 | x |
| 2019-03-31 | $20.68 | $4.70 | x |
| 2020-03-31 | $176.28 | $4.70 | x |
| 2021-03-31 | $8.65 | $4.70 | x |
| 2022-03-31 | $9.28 | $4.70 | x |
| 2023-03-31 | $4.72 | $4.70 | x |
| 2024-03-31 | $0.20 | $4.70 | x |
| 2025-03-31 | $-0.07 | $4.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Portage Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1056.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 0.00% | 0.00% | 0.00x | 0.00x | $-351.31K |
| 1999 | -295.88% | 0.00% | 0.00x | 1.61x | $-327.20K |
| 2000 | -59.87% | -3877.43% | 0.01x | 1.09x | $-1.12 Million |
| 2001 | -226.09% | -1431.00% | 0.13x | 1.20x | $-1.14 Million |
| 2002 | -27356.53% | -1993.66% | 0.32x | 42.40x | $-836.05K |
| 2003 | 0.00% | -2093.53% | 0.53x | 0.00x | $-196.15K |
| 2004 | -61.32% | 0.00% | 0.00x | 1.39x | $-1.21 Million |
| 2005 | -102.14% | -1342.05% | 0.07x | 1.03x | $-4.59 Million |
| 2006 | -55.38% | -157.63% | 0.34x | 1.03x | $-2.96 Million |
| 2007 | -2.51% | -22.35% | 0.11x | 1.01x | $-718.35K |
| 2008 | -11.04% | -230.14% | 0.05x | 1.01x | $-1.06 Million |
| 2009 | -47.85% | -1302.35% | 0.03x | 1.11x | $-660.10K |
| 2010 | -54.12% | 0.00% | 0.00x | 1.44x | $-4.56 Million |
| 2011 | -42.91% | 0.00% | 0.00x | 1.08x | $-4.73 Million |
| 2012 | -51.03% | 0.00% | 0.00x | 1.55x | $-2.96 Million |
| 2013 | -49.26% | -1493.72% | 0.03x | 1.15x | $-1.77 Million |
| 2014 | -263.46% | 0.00% | 0.00x | 2.20x | $-6.54 Million |
| 2015 | -117.24% | 0.00% | 0.00x | 1.78x | $-3.38 Million |
| 2016 | -55.57% | 0.00% | 0.00x | 1.23x | $-6.73 Million |
| 2017 | 27.35% | 0.00% | 0.00x | 1.01x | $10.34 Million |
| 2018 | 1286.42% | 0.00% | 0.00x | 1.04x | $122.78 Million |
| 2019 | -2.64% | 0.00% | 0.00x | 1.74x | $-12.60 Million |
| 2020 | -5.52% | 0.00% | 0.00x | 1.79x | $-14.99 Million |
| 2021 | -15.61% | 0.00% | 0.00x | 1.72x | $-25.98 Million |
| 2022 | -13.92% | 0.00% | 0.00x | 1.61x | $-28.99 Million |
| 2023 | -137.56% | 0.00% | 0.00x | 1.30x | $-112.22 Million |
| 2024 | -1873.17% | 0.00% | 0.00x | 1.93x | $-75.74 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.75 Million |
Industry Comparison
This section compares Portage Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Portage Biotech Inc (PRTG) | $695.00K | 0.00% | 2.89x | $10.71 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more